Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
patentscope.wipo.int/search/docservic... The present invention provides antagonists of IL-17C for use in the treatment and/or prevention of atopic dermatitis and related conditions.
Ook Morphosys houdt een conference call over haar 1e kwartaal cijfers. Voor zover Galapagos aanstaande vrijdag niet iets zegt over voortgang MOR106, dan doet Morphosys dat wellicht: Planegg/Munich, Germany, April 24, 2017 MorphoSys to Host Q1 2017 Conference Call on May 3, 2017 MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first three months’ 2017 results on May 3, 2017 at 7:00 am CEST. At 3:00 pm CEST (2:00 pm BST, 9:00 am EDT), the Management Board of MorphoSys AG will host a public conference call and webcast to present MorphoSys’s first quarter interim statement 2017 and provide further details on the Company’s latest developments. Dial-in numbers (listen only): Germany: +49 89 2444 32975 United Kingdom: +44 20 3003 2666 USA: +1 202 204 1514 We request that you please dial in up to 10 minutes before the call to ensure a prompt start and a secure line. The presentation slides and webcast link will be available at the Company’s website at www.morphosys.com/conference-calls A slide-synchronized audio replay of the conference will also be available at the corporate website following the live event.
harvester schreef op 25 april 2017 19:02 :
Ook Morphosys houdt een conference call over haar 1e kwartaal cijfers.
Voor zover Galapagos aanstaande vrijdag niet iets zegt over voortgang MOR106, dan doet Morphosys dat wellicht:
Zojuist de conference call beluisterd. Had al eerder het persbericht gelezen. Als aandeelhouder van Morphosys werd ik daar vrolijk van en het lijkt erop dat ik niet de enige ben nu de koers van Morhosys aan het oplopen is. Er wordt nog steeds verwacht dat in december markttoelating verkregen wordt voor een product dat door een van haar partners in december vorig jaar een aanvraag voor markttoelating ingediend werd. Dus volgend jaar krijgt Morphosys ook royalties. Inzake het project met Galapagos (MOR106) werd in de conference call gesproken over het 4e kwartaal voor de resultaten van de huidige fase 1 studie. Die loopt as planned. Ook Morphosys bulkt van het geld dus dat zal ook geen vertraging opleveren. Dus ook goed nieuws over de samenwerking tussen Morphosys en Galapagos. Nog even wachten tot het 4e kwartaal voor nader nieuws.
Ondertussen gaat het ook met Morphosys (en haar Groningse dochter) goed: 19/05/2017 MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers 18/05/2017 MorphoSys to Present Clinical Data on Proprietary Programs at Upcoming ASCO Annual Meeting 2017 17/05/2017 MorphoSys AG Reports Outcome of Annual General Meeting 2017 03/05/2017 MorphoSys AG Reports Solid First Quarter 2017
harvester schreef op 23 mei 2017 10:17 :
Ondertussen gaat het ook met Morphosys (en haar Groningse dochter) goed:
19/05/2017
MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers
18/05/2017
MorphoSys to Present Clinical Data on Proprietary Programs at Upcoming ASCO Annual Meeting 2017
17/05/2017
MorphoSys AG Reports Outcome of Annual General Meeting 2017
03/05/2017
MorphoSys AG Reports Solid First Quarter 2017
De koers van Morphosys loopt nu wel snel op: inmiddels boven de EUR 65 tot nu toe EUR 2,60 erbij vandaag ofwel ruim 4%.
harvester schreef op 24 mei 2017 11:53 :
[...]
De koers van Morphosys loopt nu wel snel op: inmiddels boven de EUR 65 tot nu toe EUR 2,60 erbij vandaag ofwel ruim 4%.
De koers staat nu op EUR 66 en het is duidelijk waarom: J+J gebruikt priority voucher voor Guselkumab in in moderate to severe plaque psoriasis, maar gaat ook 3 additionele fase 3 studies starten waarvan 1 in Crohs disease. >> mogelijk concurrentie voor Galapagos+ABBVIE (en voor Vertex). May 24, 2017 / 11:32 am, CEST Planegg/Munich, Germany, May 24, 2017 MorphoSys Announces That Its Licensee Janssen Reported Updates on the Development of Guselkumab MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its licensee Janssen Research & Development, LLC (Janssen), has provided an update on the development of guselkumab. Guselkumab is a fully human anti-IL-23 monoclonal antibody developed by Janssen, and was generated by MorphoSys utilizing its proprietary HuCAL antibody library technology. According to information provided recently, Janssen has applied a priority review voucher to the guselkumab biologics license application (BLA) with the goal of accelerating the approval process in moderate to severe plaque psoriasis. Pending a positive decision by the FDA, Janssen anticipates a potential US approval of guselkumab may be possible in Q3 2017. In addition, Janssen announced plans for three new phase 3 clinical trials with guselkumab. These include a phase 3 study to evaluate the comparative efficacy of guselkumab versus secukinumab (Cosentyx(R)) for the treatment of moderate to severe plaque-type psoriasis (ECLIPSE study); a planned phase 3 study in psoriatic arthritis; and plans for a phase 3 program Crohn's disease. According to Janssen the ECLIPSE study has been initiatied and the psoriatic arthritis study is planned to begin enrolling in Q3 2017. "Following on from our licensee Janssen's successful phase 3 studies VOYAGE 1, VOYAGE 2 and NAVIGATE in moderate to severe plaque psoriasis and the regulatory filings for approval submitted in the U.S. and Europe, we were delighted to learn of Janssen's recent update on guselkumab," said Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "We are also delighted to hear of Janssen's plans for potentially expanding the range of indications of guselkumab."
Morphosys+J+J :FDA Approval for Tremfya(TM) (Guselkumab) for Plaque Psoriasis 2017-07-13T23:10:32 CET Adhoc: MorphoSys Announces That Its Licensee Janssen Has Received US FDA Approval for Tremfya(TM) (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis Adhoc: MorphoSys Announces That Its Licensee Janssen Has Received US FDA Approval for Tremfya(TM) (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis First antibody generated from MorphoSys's HuCAL library technology to receive marketing approval MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its licensee Janssen Biotech, Inc. (Janssen), has reported that the U.S. Food and Drug Administration (FDA) has approved Tremfya(TM) (guselkumab) for the treatment of patients with moderate to severe plaque psoriasis. Tremfya is a fully human anti-IL-23 monoclonal antibody developed by Janssen and was generated utilizing MorphoSys's proprietary HuCAL antibody library technology. MorphoSys will receive a milestone payment from Janssen in connection with the BLA approval. Financial details were not disclosed. MorphoSys will provide information on on financial guidance at a later date. End of adhoc announcement
Planegg/Munich, Germany, July 13, 2017 MorphoSys Announces That Its Licensee Janssen Has Received US FDA Approval for Tremfya(TM) (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis First antibody generated from MorphoSys's HuCAL library technology to receive marketing approval MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its licensee Janssen Biotech, Inc. (Janssen), has reported that the U.S. Food and Drug Administration (FDA) has approved Tremfya(TM) (guselkumab) for the treatment of patients with moderate to severe plaque psoriasis. Tremfya is a fully human anti-IL-23 monoclonal antibody developed by Janssen and was generated utilizing MorphoSys's proprietary HuCAL antibody library technology. MorphoSys will receive a milestone payment from Janssen in connection with the BLA approval. Financial details were not disclosed. Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG, said: "It is a very exciting day for all of us at MorphoSys to have the first antibody generated from our proprietary HuCAL antibody technology receive marketing approval. We are grateful to Janssen for their development efforts and look forward to the launch of Tremfya. Plaque psoriasis is a chronic disease affecting millions of people worldwide, and it is fantastic news that this therapy will now be made available to patients living with moderate to severe disease. We are also very pleased that Janssen is pursuing the development of Tremfya in several additional indications." Dr. Moroney continued: "With more than 100 MorphoSys compounds currently in development, we look forward to advancing novel antibodies in a wide variety of serious diseases where we see a strong need for alternative treatment options." Further information can be found in the press release issued by Janssen on July 13, 2017. MorphoSys will provide information on on financial guidance at a later date. About Psoriasis Psoriasis is a chronic, autoimmune inflammatory disorder that results in the overproduction of skin cells, characterised by raised, inflamed, scaly, red lesions, or plaques, which can cause itching and physical pain. It is estimated that as many as 125 million people worldwide have psoriasis, including 14 million Europeans, and approximately 20% of people affected have cases that are considered moderate to severe. About MorphoSys: MorphoSys is committed to developing exceptional new treatments for patients suffering from serious diseases. A leader in the field of therapeutic antibodies today, MorphoSys is driven by the ambition of creating the most valuable pipeline of biopharmaceuticals in the biotechnology industry. Based on its proprietary technology platforms, MorphoSys, together with its partners, has built a therapeutic pipeline of more than 110 programs in R&D, around a quarter of which is currently in clinical development. In its proprietary development segment, MorphoSys, alone or with partners, is developing new therapeutic candidates, mainly focusing on cancer and inflammation. In its partnered discovery segment, MorphoSys uses its technologies to discover new drug candidates for pharmaceutical partners and participates from the programs' further development success, through success-based payments and royalties. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit www.morphosys.com. HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group.
Aandeel MorphoSys CHX:MOR, DE0006632003 koers begint aardig op te lopen, na dit goede nieuws.Ik denk dat nog niet iedereen de betekenis hiervan beseft. J+J kan beginnen met verkoop dus Morphosys gaat royalty inkomsten krijgen. Dat is ook goed voor investeringen in andere programma's zoals Mor106 met Galapagos. Handelen Volgen Realtime (EUR) Verschil Volume Bied Laat Vandaag 52W 67,710 +5,290 (+8,47%) 09:30:16 7.130 Gem. 23,9K -70% 67,460 134 67,720 84 67,060 67,980 35,775 66,620
Marketcap is rond de € 2 mrd (incl. € 340 mln cash) en wat een pipeline hebben ze zeg. Mooi bedrijf.
Bioteg71 schreef op 14 juli 2017 10:56 :
Marketcap is rond de € 2 mrd (incl. € 340 mln cash) en wat een pipeline hebben ze zeg. Mooi bedrijf.
Inderdaad en mijn een na grootste investering. Overigens zijn de relaties tussen Galapagos en Morphosys uitstekend. Enkele jaren geleden zei de CEO van Morphosys in verband met de samenwerking in het Mor106 programma "our friends at Galapagos". Over de pijplijn van Morphosys heeft iemand wel eens gezegd dat die breder lijkt dan hij is omdat zij niet met alles actief zijn. Dat kan zo zijn, maar of dat ligt aan kansen of te weinig centen weten wij geen van allen. Eind vorig jaar hebben ze met gemak extra geld opgehaald. Dat het met Guselkumab de goed kant op ging was toen wel duidelijk, maar dat J+J een priority voucher heeft ingezet en nu ook daadwerkelijk de markt op mag, maakt het financiële plaatje nog wel een stuk steviger. Ik ben benieuwd naar de aankondiging van het effect van de markttoelating op de inkomsten (wellicht een aardige milestone nu, naast de royalties) en op de plannen met de pipeline (versnelling van actieve programma's en/of activering van slapende programma's). Morphosys krijgt mogelijk hetzelfde probleem als Galapagos: een partij (J+J) die het bedrijf voor een product over wil nemen waardoor de rest van de pipeline niet meer de aandacht krijgt die het verdient in de ogen van het huidige management team. J+J heeft met de overname van Crucell op dat vlak een onplezierige reputatie opgebouwd.
MorphoSys Reports Significant Progress in its Therapeutic Programs in Second Quarter of 2017 August 03, 2017 / 7:00 am, CEST First proprietary blood cancer program MOR208 enters phase 3 clinical trial; first partnered antibody guselkumab receives market approval Conference call and webcast (in English) at 2:00pm CEST (1:00pm BST/8:00am EDT) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY), a leader in the field of therapeutic antibodies, today reported results for the second quarter of 2017. "We have seen significant progress, both with our own and our partners' drug candidates in the second quarter of 2017. Our progress was particularly evidenced by the start of a phase 3 trial with our blood cancer compound MOR208. This is the first pivotal study with a compound from our own development portfolio and a major milestone for MorphoSys," said Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "More great news for the pipeline came shortly after the quarter ended, when our partner Janssen announced US FDA approval of TremfyaTM (guselkumab) in plaque psoriasis. This is the best possible validation for our antibody technology and a landmark in the history of MorphoSys. We're extremely happy that TremfyaTM, the first approved product based on our technology, is now available to patients in the US, living with moderate to severe plaque psoriasis." MorphoSys continues to focus on the research and development of drug candidates. In the second quarter of 2017, group revenues amounted to EUR 11.7 million, comparable with the revenue level in Q2 2016 (EUR 12.2 million)..... In the Proprietary Development segment, MorphoSys focuses its activities on research and clinical development of its own drug candidates in cancer and inflammation. Earnings before interest and taxes (EBIT) in Q2 2017 amounted to EUR -15.4 million (Q2 2016: EUR -9.5 million). As expected, the operational loss reflects increased spending for the clinical development of the Company's proprietary drug candidates. Three phase 2 studies started with the Company's lead program MOR208 in blood cancer indications during 2016, one of which transitioned into a phase 3 clinical trial in Q2 2017. Financial guidance confirmed For the financial year 2017, MorphoSys continues to expect Group revenues in the range of EUR 46 to 51 million. This guidance includes a milestone payment for the TremfyaTM approval. Since royalties for TremfyaTM cannot be accurately projected shortly after the approval, the Company will review its guidance as soon as the revenue uptake allows for reliable projections for the financial year 2017. "Based on our strong cash position, we continue to drive our proprietary portfolio forward. In particular we will focus on the phase 3 development of our blood cancer candidate MOR208. The approval of TremfyaTM marks our transition to a company whose revenues will be increasingly based on recurring income from product sales. This will contribute to the funding of our proprietary development activities," stated Jens Holstein, Chief Financial Officer of MorphoSys AG. Operational outlook for 2017 In the Proprietary Development segment, MorphoSys expects the following events in 2017:... - MOR106: Presentation of results from the ongoing phase 1 trial of MOR106, being co-developed with Galapagos in atopic dermatitis. In its Partnered Discovery segment, the following events were reported after the end of the reporting period or are further expected: - TremfyaTM (guselkumab): the first partner-developed therapeutic antibody based on MorphoSys's HuCAL technology has received FDA approval and is now available to patients in the US, according to MorphoSys's partner Janssen. Moreover, guselkumab is currently in review for market approval also in Europe. - For the remainder of the year, results may be disclosed from up to 25 different clinical studies in various phases conducted by partners with antibodies based on MorphoSys technology. As always, MorphoSys is in discussions with other companies in the pharmaceutical industry about technology and/or product-based collaborations, with the goal of strengthening its participation in drug programs aimed at unmet medical needs. MorphoSys will hold its conference call and webcast today to present the second quarter 2017 and first half 2017 financial results and the further outlook for 2017. Dial-in number for the analyst conference call (in English) at 2:00 pm CEST; 1:00 pm BST; 8:00 am EDT (listen-only): Germany: +49 (0) 89 2444 32975 For UK residents: +44 (0) 20 3003 2666 For US residents: +1 202 204 1514 Please dial in 10 minutes before the beginning of the conference. A live webcast and slides will be made available at www.morphosys.com. Shortly after the conference call, a slide-synchronized audio replay of the conference and a transcript will be available on www.morphosys.com. The half year report (January - June 2017) (IFRS) is available online:www.morphosys.com/FinancialReports MorphoSys will hold a Capital Markets Day on September 5 and 6, 2017. About MorphoSys: MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Innovative technologies and smart development strategies are central to our approach. Success is created by our people, who focus on excellence in all they do, collaborate closely across disciplines and are driven by a desire to make the medicines of tomorrow a reality. Success benefits all of our stakeholders. Based on its proprietary technology platforms, particularly in the field of fully human therapeuc antibodies, MorphoSys, together with its partners, has built a therapeutic pipeline of more than 110 programs in R&D, around a quarter of which is currently in clinical development. In its proprietary development segment, MorphoSys, alone or with partners, is developing new therapeutic candidates, mainly focusing on cancer and inflammation. In its partnered discovery segment, MorphoSys uses its technologies to discover new drug candidates for pharmaceutical partners and participates from the programs' further development success, through success-based payments and royalties. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit www.morphosys.com.
conference agenda MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences: Commerzbank Sector Conference Date: August 29, 2017 Venue: Frankfurt, Germany Participants: Jens Holstein, Chief Financial Officer of MorphoSys AG Anke Linnartz, Head of Corporate Communications & IR MorphoSys Capital Markets Day Date: September 5 and 6, 2017 Venue: London, UK and New York, USA Participants: Management Board of MorphoSys AG Anke Linnartz, Head of Corporate Communications & IR Goldman Sachs 7th Annual Biotech Symposium Date: September 8, 2017 Venue: London, UK Participants: Jens Holstein, Chief Financial Officer of MorphoSys AG Anke Linnartz, Head of Corporate Communications & IR Berenberg and Goldman Sachs Sixth German Corporate Conference Date: September 18, 2017 Venue: Munich, Germany Participants: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG Anke Linnartz, Head of Corporate Communications & IR Baader Investment Conference Date: September 20, 2017 Venue: Munich, Germany Participants: Jens Holstein, Chief Financial Officer of MorphoSys AG Anke Linnartz, Head of Corporate Communications & IR A PDF version of all presentations and, where available, a webcast link to the respective event will be available at www.morphosys.com.
Planegg/Munich, Germany, London, UK, September 5, 2017 MorphoSys Presents Vision for Growth at its Capital Markets Day - Company is exploring fastest path to market for proprietary blood cancer program MOR208 - Working to secure a deal for proprietary blood cancer program MOR202 - Phase 1 data for MOR106 in atopic dermatitis expected very soon - New early stage programs announced - Ambition to bring one new compound into the clinic every 18 months - Financial guidance for FY 2017 re-confirmed MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY), a leader in the field of therapeutic antibodies, is today hosting its Capital Market Day in London. The Management of MorphoSys AG updated analysts and investors on the Company's growth and development strategy and confirmed its financial guidance for 2017. "We're excited about the progress in our pipeline. The main focus of our attention is our blood cancer program MOR208, for which we have promising clinical data in DLBCL, a particularly aggressive form of lymphoma. We're working hard to identify the fastest possible path to market for this novel drug candidate", said Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG in his opening remarks. "Based on the clinical data we've seen in our clinical trial L-MIND, MOR208 may offer an efficacious, safe, convenient, and affordable treatment to bring patients into remission and keep them there." Beyond MOR208, MorphoSys is working to secure a deal for its second blood cancer program MOR202, now based on a data package from the phase 1b/2 trial. For MOR106, an antibody in joint development with Galapagos for atopic dermatitis, headline data from an ongoing phase 1 clinical trial is expected to be released soon. The Company's rights to MOR209, an immunotherapeutic for the treatment of metastatic castration resistant prostate cancer, which was in joint development with its originator Aptevo Therapeutics, were recently returned to Aptevo following a portfolio review. Ambition to bring one new compound into clinic every 18 months Based on its technological leadership MorphoSys aims to bring a new investigational drug into the clinic every 18 months. A constant inflow of new and innovative drug candidates will ensure that the Company's broad portfolio of proprietary clinical assets is sustained in the future. The focus on its own programs clearly demonstrates the company's firm goal to become a fully integrated bio-pharmaceutical company. Announcement of new, early-stage programs MorphoSys also highlighted its earlier stage programs, including a new immuno-oncology program aimed at reversing immunosuppression in cancer. The program is based on a proprietary MorphoSys antibody targeting the C5a receptor, which is intended to enhance patients' immune systems in eradicating tumor cells. The antibody will enter preclinical development this year and is expected to enter the clinic in 2019. Further, the Company revealed early progress in two antibody programs against tumor-associated MHC-peptide targets and announced two bi-specific antibody formats based on proprietary CD3 and 4-1BB antibodies. Financial guidance for FY 2017 re-confirmed For the financial year 2017, MorphoSys continues to expect Group revenues in the range of EUR 46 to 51 million. Proprietary R&D expenses were confirmed to be in a corridor of EUR 85 to 95 million. The Company confirmed its guidance for earnings before interest and taxes (EBIT) of EUR -75 to -85 million. This guidance does not include any additional revenue from potential future collaborations and/or licensing partnerships nor effects from potential in-licensing or co-development deals for new development candidates. "With our strong cash position, we continue to drive forward our proprietary portfolio. In particular, we are focused on the pivotal development of our blood cancer candidate MOR208. Our maturing partnered pipeline is expected to generate increasing cashflows from royalties in the years to come. This will contribute to the funding of our proprietary development activities," said Jens Holstein, Chief Financial Officer of MorphoSys AG. "We see blockbuster potential for Janssen's TremfyaTM, not only for the US psoriasis market, but also in other jurisdictions and indications." The Capital Markets Day is taking place in London on September 5, 2017 and in New York on September 6, 2017. Presentations and other information material given at the Capital Markets Day are available on our website: www.morphosys.com.
September 05, 2017 / 10:45 am, CEST Planegg/Munich, Germany, London, UK, September 5, 2017 MorphoSys Presents Vision for Growth at its Capital Markets Day - Company is exploring fastest path to market for proprietary blood cancer program MOR208 - Working to secure a deal for proprietary blood cancer program MOR202 - Phase 1 data for MOR106 in atopic dermatitis expected very soon - New early stage programs announced - Ambition to bring one new compound into the clinic every 18 months - Financial guidance for FY 2017 re-confirmed MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY), a leader in the field of therapeutic antibodies, is today hosting its Capital Market Day in London. The Management of MorphoSys AG updated analysts and investors on the Company's growth and development strategy and confirmed its financial guidance for 2017. "We're excited about the progress in our pipeline. The main focus of our attention is our blood cancer program MOR208, for which we have promising clinical data in DLBCL, a particularly aggressive form of lymphoma. We're working hard to identify the fastest possible path to market for this novel drug candidate", said Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG in his opening remarks. "Based on the clinical data we've seen in our clinical trial L-MIND, MOR208 may offer an efficacious, safe, convenient, and affordable treatment to bring patients into remission and keep them there." Beyond MOR208, MorphoSys is working to secure a deal for its second blood cancer program MOR202, now based on a data package from the phase 1b/2 trial. For MOR106, an antibody in joint development with Galapagos for atopic dermatitis, headline data from an ongoing phase 1 clinical trial is expected to be released soon. The Company's rights to MOR209, an immunotherapeutic for the treatment of metastatic castration resistant prostate cancer, which was in joint development with its originator Aptevo Therapeutics, were recently returned to Aptevo following a portfolio review. Ambition to bring one new compound into clinic every 18 months Based on its technological leadership MorphoSys aims to bring a new investigational drug into the clinic every 18 months. A constant inflow of new and innovative drug candidates will ensure that the Company's broad portfolio of proprietary clinical assets is sustained in the future. The focus on its own programs clearly demonstrates the company's firm goal to become a fully integrated bio-pharmaceutical company. Announcement of new, early-stage programs MorphoSys also highlighted its earlier stage programs, including a new immuno-oncology program aimed at reversing immunosuppression in cancer. The program is based on a proprietary MorphoSys antibody targeting the C5a receptor, which is intended to enhance patients' immune systems in eradicating tumor cells. The antibody will enter preclinical development this year and is expected to enter the clinic in 2019. Further, the Company revealed early progress in two antibody programs against tumor-associated MHC-peptide targets and announced two bi-specific antibody formats based on proprietary CD3 and 4-1BB antibodies. Financial guidance for FY 2017 re-confirmed For the financial year 2017, MorphoSys continues to expect Group revenues in the range of EUR 46 to 51 million. Proprietary R&D expenses were confirmed to be in a corridor of EUR 85 to 95 million. The Company confirmed its guidance for earnings before interest and taxes (EBIT) of EUR -75 to -85 million. This guidance does not include any additional revenue from potential future collaborations and/or licensing partnerships nor effects from potential in-licensing or co-development deals for new development candidates. "With our strong cash position, we continue to drive forward our proprietary portfolio. In particular, we are focused on the pivotal development of our blood cancer candidate MOR208. Our maturing partnered pipeline is expected to generate increasing cashflows from royalties in the years to come. This will contribute to the funding of our proprietary development activities," said Jens Holstein, Chief Financial Officer of MorphoSys AG. "We see blockbuster potential for Janssen's TremfyaTM, not only for the US psoriasis market, but also in other jurisdictions and indications." The Capital Markets Day is taking place in London on September 5, 2017 and in New York on September 6, 2017. Presentations and other information material given at the Capital Markets Day are available on our website: www.morphosys.com. About MorphoSys: MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Innovative technologies and smart development strategies are central to our approach. Success is created by our people, who focus on excellence in all they do, collaborate closely across disciplines and are driven by a desire to make the medicines of tomorrow a reality. Success benefits all of our stakeholders. Based on its proprietary technology platforms, particularly in the field of fully human therapeuc antibodies, MorphoSys, together with its partners, has built a therapeutic pipeline of more than 110 programs in R&D, around a quarter of which is currently in clinical development. In its proprietary development segment, MorphoSys, alone or with partners, is developing new therapeutic candidates, mainly focusing on cancer and inflammation. In its partnered discovery segment, MorphoSys uses its technologies to discover new drug candidates for pharmaceutical partners and participates from the programs' further development success, through success-based payments and royalties. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit www.morphosys.com. HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group. Tremfya(TM) is a trademark of Janssen Biotech, Inc.This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned. For more information, please contact: MorphoSys AG Anke Linnartz Head of Corporate Communications & IR Jochen Orlowski Associate Director Corporate Communications & IR Alexandra Goller Senior Manager Corporate Communications & IR Tel: +49 (0) 89 / 899 27-404investors@morphosys.com
Thursday, September 7, 2017 - 4:30pm - dus nog even wachten tot de volgende Morphosys webcast na die van capital markets day. Misschien dan voldoende binnen gedruppeld voro een gezamenlijk persbericht inzake MOR106: Webcast: Wells Fargo Securities 2017 Healthcare Conference Dr. Simon Moroney presents the Company at the Wells Fargo Securities 2017 Healthcare Conference, Boston, USA, on Thursday, September 7, 2017, 10:35am EDT, (4:35pm CEST, 3:35pm BST). Go to Webcast link:cc.talkpoint.com/well001/090617a_as/?...
Aandeel MorphoSys CHX:MOR, DE0006632003 koers loopt op van Morphosys :65.58 Kennelijk komen de presentaties van Morphosys niet alleen bij mij goed over. Handelen Volgen Realtime (EUR) Verschil Volume Bied Laat Vandaag 52W 65,580 +1,980 (+3,11%) 10:54:54 23.613 Gem. 38,4K -38%
MORPHOSYS AG 66,880 12:13:00 +3,280 +5,16% verder opgelopen..harvester schreef op 7 september 2017 11:01 :
Aandeel MorphoSys CHX:MOR, DE0006632003 koers loopt op van Morphosys :65.58
Kennelijk komen de presentaties van Morphosys niet alleen bij mij goed over.
Handelen
Volgen
Realtime (EUR) Verschil Volume Bied Laat Vandaag 52W
65,580 +1,980 (+3,11%) 10:54:54
23.613
Gem. 38,4K
-38%
Media Release Planegg/Munich, Germany, September 18, 2017 MorphoSys Announces that its Licensee Janssen received CHMP Positive Opinion for Tremfya™ (Guselkumab) Recommending Approval in Europe Janssen’s TremfyaTM could become the first antibody generated from MorphoSys’s HuCAL technology to receive market approval in Europe following U.S. FDA approval for the treatment of patients with moderate to severe plaque psoriasis in July 2017 MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that Janssen-Cilag International NV (Janssen) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of Tremfya™ (guselkumab) for the treatment of patients with moderate to severe plaque psoriasis in Europe. TremfyaTM is a fully human anti-IL-23 monoclonal antibody developed by Janssen and was generated utilizing MorphoSys’s proprietary HuCAL antibody technology. SImon Moroney (CEO Morphosys): Assuming approval by the European Commission, we expect this drug to provide a valuable treatment option for patients living with moderate to severe plaque psoriasis in Europe, after Janssen received U.S. FDA approval for TremfyaTM for the same indication earlier this year.” MorphoSys is eligible to royalties on net sales based on the product sales of Janssen related to TremfyaTM.
Aandeel MorphoSys CHX:MOR, DE0006632003 EUR 68,600 +1,760 (+2,63%) 11:45:25 7.559 Aardige stijging nav het bericht van vandaag, maar weinig volume. Misschien wil gewoon niemand meer verkopen.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)